ORIC pharmaceuticals appoints Valeria Fantin, Ph.D. as Chief Scientific Officer

South San Francisco, CA – August 17, 2015 – ORIC Pharmaceuticals, Inc., a privately-held company dedicated to the discovery and development of novel therapeutics for the treatment of cancer, announced today the appointment of Valeria Fantin, Ph.D. as Chief Scientific Officer.

Dr. Fantin is a biopharmaceutical executive with 11 years of experience in exploratory biology and oncology drug discovery and development. Prior to joining ORIC, she was Vice President of Tumor Cell Biology at Pfizer, responsible for advancing small molecules from target validation to Phase 2 proof-of-concept. Dr. Fantin was also responsible for identifying business development opportunities and leading strategic alliances to help broaden Pfizer’s efforts in oncology research. Dr. Fantin also held leadership positions at Agios Pharmaceuticals where she created and advanced an exploratory program of novel cancer metabolism targets into drug discovery and led the execution of the company’s flagship program. Her earlier career as a researcher included positions focused on epigenetics and kinase drug discovery projects with Merck Research Laboratories and ARIAD Pharmaceuticals. Throughout her career, she has contributed to the discovery of numerous compounds currently under clinical evaluation and the development of a number of FDA-approved drugs.

“Valeria Fantin brings an impressive track-record of leadership in cancer biology to the ORIC management team,” said Peter Svennilson, ORIC’s acting chief executive officer. “She has broad experience in drug discovery and development in oncology that will be instrumental towards establishing a rigorous discovery platform at ORIC.”

“ORIC is an early-stage company that has quickly established a solid foundation for drug discovery and development with an outstanding research team and highly-engaged scientific advisors,” said Dr. Fantin. “I look forward to joining the efforts to identify drug candidates that can be advanced to the clinic and demonstrate clinical proof-of-concept for meaningful improvements in the treatment of cancer.”

About ORIC Pharmaceuticals
ORIC is a privately-held pharmaceutical company dedicated to discovering and developing novel therapies for treatment-resistant cancers. While recent advances with targeted therapeutics have extended prognoses in many disease settings, cancers often develop resistance to these drugs. ORIC has assembled a world-class scientific team dedicated to the discovery of therapies that can meaningfully improve clinical outcomes for these patients.

ORIC was founded by two world-class experts in oncology, Dr. Charles Sawyers and Dr. Scott Lowe, who have strong records of discovering innovative treatments and targets for cancer. ORIC has assembled a team of highly-experienced scientists who are executing multiple drug discovery strategies targeting the mechanisms that allow tumors to become resistant to current therapies. In addition, the scientific team has unparalleled access to the operational expertise of advisors who have devoted their careers to oncology drug development. Finally, the Company is supported by investors with extensive experience in both drug development and the financing of life science companies.

ORIC Pharmaceuticals is headquartered in South San Francisco, California. For more information, please visit the Company’s website at http://www.oricpharma.com.